Diphoxazide is the anticonvulsant and psychosedative agent.

Diprafenone closely resembles propafenone in both structure and function. It is beta adrenoceptor antagonists and sodium channel antagonists. Diprafenone is highly protein bound in plasma. It has demonstrated efficacy against supraventricular and ventricular arrhythmias in clinical trials. Diprafenone produced first-degree atrioventricular block in 6/20 patients tested with coronary artery disease and sustained ventricular tachycardia. Intravenous application of diprafenone significantly increased atrioventricular nodal conduction time as well as the effective refractory periods of the right ventricle and the accessory pathway in both the antegrade and retrograde directions in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia.

Diproqualone was used primarily for the treatment of inflammatory pain associated with osteoarthritis. The analgesic activity of diproqualoneis synergistic with that of noramidopyrine. It also display anti-inflammatory action in the rat, inhibiting plantar edema with dextran or serotonin, atopic edema from ovalbumin, etc. It has spasmolytic, anticholinergic and antihistaminic action in higher doses. It is not hypnotic and has no anticonvulsant effects. The therapeutic symptoms for diproqualone are all types of pain: postoperative, posttraumatic, dental, neuritis, anti-inflammatory arthritis, etc.

Diprofene is a myotropic antispasmodic with pronounced vasodilating effect. It has minor anticholinergic and local anesthetic properties. Antispasmodic action develops gradually. Diprofene is indicated for the treatment of peripheral vasospasms (obliterating endarteritis, Raynaud's disease, etc.) and spasm of smooth muscles of internal organs (gastric colic, intestinal colic, renal colic, biliary colic). Adverse effects are: dizziness, headache, nausea, numbness of the oral mucosa.

Metethoheptazine (WY-535) is an analgesic agent.

Caloxetate Trisodium is triazaundecanedioic acid derivative patented by German pharmaceutical company as liver-specific magnetic resonance imaging contrast agent.

Lensiprazine (SLV314) is a potent D2 receptor antagonist in vitro and have a considerable in vitro affinity for serotonin reuptake sites. It capable of antagonizing apomorphine-induced climbing behavior, disrupting CAR activity and potentiating 5-hydroxytryptophan (5-HTP) behavior. SLV314 has also been found to antagonize amphetamine- and ketamine-stimulated locomotor activity and methylphenidate-induced gnawing and stimulated behaviors, furthermore, a significant dose discrepancy was seen between the antipsychotic and cataleptogenic effects of SLV314. Lensiprazine demonstrated putative antipsychotic and selective serotonin reuptake inhibitor potential.

BMS-908662 (previously known as XL281) is a small molecule Raf kinase inhibitor that lies immediately downstream of RAS and are key components of the RAS/RAF/MEK/ERK kinase-signaling pathway. Bristol-Myers Squibb has received an exclusive worldwide license to develop and commercialize antineoplastic agent XL281. BMS-908662 participated in phase I development for the treatment of patients with melanoma and in combination with cetuximab for patients with colorectal cancer. However, further, development has been discontinued.

Neocinchophen is an analgesic and uricosuric. Cinchophen and neocinchophen (introduced by Chemische Fabrik auf Aktien as Atophan and Novatophan) were being advertised as superior substitutes for salicylates in the treatment of rheumatic fever. Chemically, cinchophen is phenylcinchoninic acid, and neocinchophen is the ethyl ester of its methyl derivative.